KRAS and colon carcinoma: Second, we showed that CIP2A is downregulated after inhibiting the MAPK pathway in three colon carcinoma cell lines; downregulation in cell lines harbouring a KRAS mutation (HCT116, SW620) is more pronounced than in Caco2 not harbouring a MAPK-pathway mutation.